Investing.com -- Shares of AnaptysBio, Inc. (NASDAQ:ANAB) surged over 60% following the announcement of positive results from a Phase 2b trial of rosnilimab, its investigational treatment for ...

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the fourth quarter and year ended ...

Format – Presentation and one-on-one investor meetings Date and Time – Wednesday, Mar. 12, 2025 at 8:30am ET / 5:30am PT Live webcasts of the fireside chats and ...

To learn more, visit www.AnaptysBio.com or follow us on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the "safe harbor ...

Format – Presentation and one-on-one investor meetings Date and Time – Wednesday, Mar. 12, 2025 at 8:30am ET / 5:30am PT Live webcasts of the fireside chats and presentation will be available on the ...

Disclaimer: Rho is a financial technology company, not a bank. Checking and card services are offered through Webster Bank, N.A., an FDIC member, while savings account services are provided by ...

The FDA has accepted Selecta Biosciences' (SELB +3.3%) IND seeking approval to start clinical development of the combination of SVP-Rapamycin and LMB-100 (SEL-403) for the ...

Disclaimer: Rho is a fintech company, not a bank. Checking and card services provided by Webster Bank, N.A., member FDIC; savings account services provided by American Deposit Management Co. and its ...

He currently serves as a director of two other publicly-traded life science companies, Galapagos NV and AnaptysBio. “As the largest current stockholder of Zymeworks, we at EcoR1 are aligned with ...